Table 1 Patient characteristics Patient... | American Society of Hematology

Table 1

Patient characteristics

Patient no.	Age, y/sex	Disease	Type of transplant	Disease status at HSCT	Time from HSCT to REL, wk	Time from relapse to TK cell infusions or death*, wk
1	30/F	DLBCL	MR	CR2	7	2
2	51/M	CML	MR	CP-CML	28	11
3	18/F	CML	MR	AP-CML	84	192
4	41/F	AML	MR	CR1	45	1
5	57/M	AML	MR	CR1	14	1
6	25/M	CML	MR	CP-CML	5	1
7	22/F	AML	MMR	REL	24	2
8	17/F	CMML	MR	CP-CMML	19	4
9	19/M	ALL	MMR	CR4	12	< 1
10	50/F	AML	MMR	REL	11	2
11	35/F	AML	MMR	REL	6	0
12	55/F	AML	MR	REL	6	< 1
13	45/F	AML	MR	CR1	5	1
14	45/M	AML	MR	REL	4	3
15	28/F	ALL	MMR	REL	6	< 1
16	47/M	FCL	MR	REL	10	3
17	48/F	MM	MR	PR	50	2
18	30/F	HD	MR	REL	26	95
19	37/F	AML	MR	REL	4	< 1
20	47/F	MM	MR	PR	8	270
21	56/F	CML	MR	CP-CML	102	1
22	28/F	HD	MR	REL	14	2
23	58/M	MCL	MR	PR	7	17
24	36/M	ALL	MR	REL	18	6*
25	50/M	ALL	MR	CR2	10	2*
26	49/M	NHL	MR	CR3	22	2*
27	49/F	ALL	MR	REL	4	< 1*
28	52/M	AML	MR	CR2	122	2*
29	29/M	ALL	MR	REL	2	2*
30	37/F	AML	MR	REL	4	1*

Patient no.	Age, y/sex	Disease	Type of transplant	Disease status at HSCT	Time from HSCT to REL, wk	Time from relapse to TK cell infusions or death*, wk
1	30/F	DLBCL	MR	CR2	7	2
2	51/M	CML	MR	CP-CML	28	11
3	18/F	CML	MR	AP-CML	84	192
4	41/F	AML	MR	CR1	45	1
5	57/M	AML	MR	CR1	14	1
6	25/M	CML	MR	CP-CML	5	1
7	22/F	AML	MMR	REL	24	2
8	17/F	CMML	MR	CP-CMML	19	4
9	19/M	ALL	MMR	CR4	12	< 1
10	50/F	AML	MMR	REL	11	2
11	35/F	AML	MMR	REL	6	0
12	55/F	AML	MR	REL	6	< 1
13	45/F	AML	MR	CR1	5	1
14	45/M	AML	MR	REL	4	3
15	28/F	ALL	MMR	REL	6	< 1
16	47/M	FCL	MR	REL	10	3
17	48/F	MM	MR	PR	50	2
18	30/F	HD	MR	REL	26	95
19	37/F	AML	MR	REL	4	< 1
20	47/F	MM	MR	PR	8	270
21	56/F	CML	MR	CP-CML	102	1
22	28/F	HD	MR	REL	14	2
23	58/M	MCL	MR	PR	7	17
24	36/M	ALL	MR	REL	18	6*
25	50/M	ALL	MR	CR2	10	2*
26	49/M	NHL	MR	CR3	22	2*
27	49/F	ALL	MR	REL	4	< 1*
28	52/M	AML	MR	CR2	122	2*
29	29/M	ALL	MR	REL	2	2*
30	37/F	AML	MR	REL	4	1*

REL indicates, relapse; F, female; DLBCL, diffuse large B-cell lymphoma; MR, matched related; CR, complete remission; M, male; CML, chronic myeloid leukemia; CP-CML, chronic-phase CML; AP-CML, accelerated-phase CML; AML, acute myelogenous leukemia; MMR, mismatched related; CMML, chronic myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; FCL, follicular cell lymphoma; MM, multiple myeloma; PR, partial remission; HD, Hodgkin lymphoma; and MCL, mantle cell lymphoma.

Time from relapse to death.

View Large

This Feature Is Available To Subscribers Only